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Abstract
Increased activation of the major pro‐inflammatory NF‐κB pathway leads to numer-
ous age‐related diseases, including chronic liver disease (CLD). Rapamycin, an inhibi-
tor of mTOR, extends lifespan and healthspan, potentially via suppression of
inflammaging, a process which is partially dependent on NF‐κB signalling. However,
it is unknown if rapamycin has beneficial effects in the context of compromised
NF‐κB signalling, such as that which occurs in several age‐related chronic diseases.
In this study, we investigated whether rapamycin could ameliorate age‐associated
phenotypes in a mouse model of genetically enhanced NF‐κB activity (nfκb1−/−)
characterized by low‐grade chronic inflammation, accelerated aging and CLD. We
found that, despite showing no beneficial effects in lifespan and inflammaging, rapa-
mycin reduced frailty and improved long‐term memory, neuromuscular coordination
and tissue architecture. Importantly, markers of cellular senescence, a known driver
of age‐related pathology, were alleviated in rapamycin‐fed animals. Our results indi-
cate that, in conditions of genetically enhanced NF‐κB, rapamycin delays aging phe-
notypes and improves healthspan uncoupled from its role as a suppressor of
inflammation.
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1 | INTRODUCTION
Chronic inflammation is a major factor underpinning aging and major
age‐related diseases, a process known as inflammaging (Franceschi
et al., 2007). Misregulation of the NF‐κB pathway, a major regulator
of inflammaging, occurs in numerous age‐associated diseases, includ-
ing cancer (Courtois & Gilmore, 2006).
NF‐κB also plays a key role in cellular senescence, a state of irre-
versible cell‐cycle arrest induced by various forms of cellular stress,
acting as a master regulator of the senescence‐associated secretory
phenotype (SASP) (Chien et al., 2011). The SASP can have beneficial
effects such as the facilitation of immune surveillance and the clear-
ance of senescent cells (Kang et al., 2011). However, an age‐depen-
dent accumulation of senescent cells resulting in a chronic SASP is
thought to play a causal role in age‐related pathology and cancer
induction (Birch & Passos, 2017).
The NF‐κB signalling is tightly associated with the mechanistic
target of rapamycin (mTOR) pathway to modulate age‐ and senes-
cence‐associated phenotypes. mTOR is a key modulator of lifespan,
as evidenced by increased longevity in a range of model organisms,
from yeast to mice, upon its inhibition (Johnson, Rabinovitch, & Kae-
berlein, 2013a). The drug rapamycin is an inhibitor of mTOR complex
1 (mTORC1) and increases lifespan and delays the onset of age‐re-
lated pathologies in mice (Harrison et al., 2009). Rapamycin is also a
key inhibitor of senescence and the SASP at multiple levels: Rapamy-
cin can inhibit the translation of IL‐1α, a key regulator of the SASP
(Laberge et al., 2015) and of MK2 kinase which controls the stability
of mRNA encoding for several SASP components (Herranz et al.,
2015). Moreover, rapamycin can inhibit mitochondrial ROS‐induced
NF‐κB activation during senescence (Correia‐Melo et al., 2016).
Importantly, rapamycin has been shown to suppress the tumour‐pro-
moting abilities of senescent cells (Herranz et al., 2015; Laberge
et al., 2015), suggesting that some of the beneficial effects of rapa-
mycin in vivo are partly mediated by its ability to act as a SASP sup-
pressor, limiting inflammaging and cancer development.
While evidence indicates that rapamycin ameliorates inflamma-
tory phenotypes and improves a wide range of healthspan traits dur-
ing aging in the absence of enforced inflammation, the effectiveness
of rapamycin in conditions where NF‐κB signalling is compromised
such as during several age‐related diseases is still unknown.
In this study, we investigated the impact of rapamycin treatment
in a mouse model showing premature aging phenotypes driven by
genetically enhanced NF‐κB activation, the nfκb1 knockout (nfκb1−/−)
mouse (Jurk et al., 2014; Wilson et al., 2015). nfκb1−/− mice have
increased inflammation due to the absence of the NF‐κB1 (p50) sub-
unit, which under normal conditions acts as a suppressor of NF‐κB
activity by competing with RelA (the classic pro‐inflammatory NF‐κB
subunit)‐containing dimers and by recruiting histone deacetylase 1
(HDAC1) which tightly packs DNA causing the active repression of
transcription (Cartwright, Perkins, & C LW, 2016).
Here, we found that lifelong treatment with rapamycin does not
impact on the lifespan of male nfκb1−/− mice, but improves health-
span, including long‐term memory, neuromuscular coordination and
forelimb grip strength, and reduces overall frailty. Moreover, age‐as-
sociated phenotypes such as increased cardiac hypertrophy, lung
emphysema and skin epidermal thinning observed in nfκb1−/− mice
were ameliorated following rapamycin supplementation. While rapa-
mycin decreased senescent markers in nfκb1−/− mice, no significant
reduction in the pro‐inflammatory phenotype was observed. Our
findings suggest that under conditions of genetically enhanced
NF‐κB activation, rapamycin results in beneficial health effects
uncoupled from its role as a suppressor of inflammation.
2 | RESULTS
2.1 | Rapamycin improves overall healthspan in
nfκb1−/− mice
To determine whether mTOR inhibition improves lifespan or health-
span in a mouse model of genetically enhanced NF‐κB activity, we
fed nfκb1−/− mice a control or rapamycin‐supplemented diet, as pre-
viously described (Harrison et al., 2009). nfκb1−/− mice fed rapamycin
showed no significant differences in mean and maximum lifespan
(Figure 1a) or in body weight throughout their life (Figure 1b) when
compared to mice fed a control diet. However, rapamycin resulted in
significant improvements in multiple parameters of clinical frailty
(Whitehead et al., 2014) with age (Figure 1c,d and Supporting Infor-
mation Table S1). Other health parameters known to decline with
age in both wild‐type (wt) and nfκb1−/− mice were improved upon
rapamycin feeding, such as long‐term memory (Figure 1e), neuromus-
cular coordination (Figure 1f) and forelimb grip strength (Figure 1g,
h).
Lung airspace enlargement, indicative of emphysematous‐like
changes, epidermal thinning of the skin and increased cardiac hyper-
trophy which occur during normal aging and prematurely in nfκb1−/−
mice, was significantly reduced following a rapamycin treatment (Fig-
ure 2a–c). nfκb1−/− mice develop chronic liver disease (CLD), charac-
terized by the emergence of dysplastic nodules, fibrosis and
increased tumour frequency (Wilson et al., 2015). Histopathological
analysis of livers from nfκb1−/− mice at 9.5 months of age did not
show fibrosis (Supporting Information Table S2), as confirmed by α‐
SMA and Sirius red analysis (Supporting Information Figure S1).
However, at later stages, moribund (debilitating state immediately
prior to death) nfκb1−/− mice showed evidence of CLD, characterized
by enhanced fibrosis and dysplasia, which was not reduced by rapa-
mycin (Supporting Information Table S2).
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2.2 | Rapamycin does not alleviate inflammation in
nfκb1−/− mice
To determine whether mTOR inhibition by rapamycin reduces
chronic inflammation in nfκb1−/− mice, we analysed serum cytokine
levels from wt and nfκb1−/− mice fed a control or rapamycin‐supple-
mented diet. While a vast array of pro‐inflammatory mediators,
including Interleukin‐6 (IL‐6), tumour necrosis factor‐alpha and vascu-
lar endothelial growth factor, was increased in the serum from
nfκb1−/− mice, rapamycin had no significant effect on these factors
(Figure 3a). Spleen enlargement, another indicator of inflammation
(Jurk et al., 2014), was also unchanged upon rapamycin treatment in
nfκb1−/− mice (Figure 3b). In addition, rapamycin did not alter the
expression of IL‐6 at the mRNA level as well as binding of the NF‐κB
subunit RelA (p65) to the IL‐6 promoter in the lungs and livers of
nfκb1−/− mice (Figure 3c,d,f,g). Furthermore, nfκb1−/− mice showed
an increased number of CD68‐positive cells, a macrophage marker,
in the liver and lungs; however, there was no significant effect of a
rapamycin‐supplemented diet (Figure 3e,h).
These results indicate that mTOR inhibition with rapamycin does
not alleviate inflammation in a mouse model of genetically enhanced
NF‐κB activity.
2.3 | Rapamycin alleviates markers of senescence
and mitochondrial dysfunction in nfκb1−/− mice
Telomere‐associated DNA damage foci (TAF) are established markers
of cellular senescence (Hewitt et al., 2012). Furthermore, increased
frequency of TAF occurs in tissues from nfκb1−/− mice when com-
pared to wild‐type (Jurk et al., 2014). To determine whether mTOR
inhibition with rapamycin affects telomere dysfunction in nfκb1−/−
mice, we analysed TAF in lung and liver tissues from nfκb1−/− mice fed
a control or rapamycin‐supplemented diet. We report a significant
increase in the mean number of TAF and percentage of TAF‐positive
lung airway epithelial cells in nfκb1−/− mice, which was reduced by
rapamycin (Figure 4a,b). We have previously reported that TAF
increase in hepatocytes with age in wt (Hewitt et al., 2012) and
nfκb1−/− mice (Jurk et al., 2014) and can be reduced by
F IGURE 1 Rapamycin prevents age‐related frailty in nf‐κb1−/− mice without impacting on lifespan. (a) Kaplan–Meier survival curves of
nf‐κb1−/− mice fed with a control (n = 44) or rapamycin‐supplemented diet (n = 24), from 4 to 5 months old until death; (b) percentage of body
weight change from baseline (start of diet) in control or rapamycin‐fed nf‐κb1−/− mice at 9.5 months and in moribund animals (n = 7–8 per
group); (c) Clinical Frailty Index at 15 and 18 months of age in nf‐κb1−/− with or without rapamycin diet (n = 8–11 per group); (d)
representative images of nf‐κb1−/− mice with or without rapamycin feeding at 18 months of age; (e) Barnes maze test in nf‐κb1−/− mice with
or without rapamycin diet (n = 9 per group); (f) neuromuscular coordination measured as % number of successful attempts (in purple) to remain
on a straight rod for 60 s (n = 4–5 per group; 9.5 months old); (g) forelimb grip strength measured as number of trials required to remain
hanging for total of 90 s (% success in purple (n = 5–9 per group; 18 months old); (h) linear regression of mean forelimb grip time (seconds). All
data are mean ± SEM. *p < 005, **p < 0.01, ***p < 0.001 (One‐way ANOVA)
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pharmacogenetic elimination of p16Ink4a‐positive senescent cells
(Ogrodnik et al., 2017). We observed that the increase in mean num-
ber of TAF and percentage of TAF‐positive hepatocytes in nfκb1−/−
mice compared to controls was suppressed by rapamycin (Figure 4c,d).
Telomere dysfunction is an important driver of cellular senescence
in vivo and in vitro (Hewitt et al., 2012). Accordingly, we analysed
markers of senescence, downstream of telomere dysfunction in lung
tissue, which shows an age‐dependent accumulation of senescent cells
and has increased frequency of senescent cells under conditions of
chronic inflammation (Birch et al., 2015; Schafer et al., 2017). mRNA
expression of the cyclin‐dependent kinase inhibitors p16 and p21 was
significantly increased in whole lungs of nfκb1−/− compared to wild‐
type mice and was reduced by rapamycin (Figure 4e).
To further determine whether rapamycin impacts on the devel-
opment of senescence in this model of chronic inflammation, we
induced senescence in mouse adult fibroblasts (MAFs), isolated from
wt or nfκb1−/− mice, by ionizing radiation (IR) and treated them with
rapamycin (Figure 4f). MAFs isolated from nfκb1−/− mice showed
increased mTOR activity as compared to wt (determined by phos-
phorylated S6 to total S6 ratio), which was reduced following rapa-
mycin treatment (Figure 4g). In agreement with previous
observations (Jurk et al., 2014), MAFs from nfκb1−/− mice showed an
enhanced senescence response to IR as compared to wt, evidenced
by increased senescence‐associated β‐galactosidase (Sen‐β‐Gal) activ-
ity and expression of p21 and p16. These markers were significantly
reduced upon rapamycin treatment in MAFs derived from both wt
and nfκb1−/− mice (Figure 4g–i and Supporting Information Figure S2).
Despite reduced expression of the cyclin‐dependent kinase inhibitors
p21 and p16, there was no rescue of proliferation (determined by
Ki67 positivity) by rapamycin following senescence induction in wt
and nfκb1−/− MAFs, consistent with previous reports (Correia‐Melo
et al., 2016) (Supporting Information Figure S2). Senescent nfκb1−/−
MAFs showed a significant increase in the secretion of SASP‐associ-
ated components IL‐6, IP‐10, KC and MCP1, when compared to
senescent wt MAFs and remained unchanged in nfκb1−/− MAFs upon
rapamycin treatment (Figure 4j).
It has been proposed that nfκb1−/− mice have accelerated aging
and senescence phenotypes, likely due to increased mitochondrial
ROS production leading to telomere dysfunction (Jurk et al., 2014).
Furthermore, rapamycin can reduce mitochondrial ROS generation
and TAF in livers of aged wt mice (Correia‐Melo et al., 2016) and
improves the survival and healthspan in a mouse model of Leigh syn-
drome, where mitochondria complex I activity is impaired (Johnson,
Yanos, et al., 2013b). Therefore, we sought to determine whether
mTOR inhibition with rapamycin impacts on mitochondrial ROS gen-
eration in the context of enforced NF‐κB activity. We found that
senescent MAFs from nfκb1−/− mice showed enhanced production
of mitochondrial‐derived ROS, as compared to MAFs from wt mice,
which was significantly reduced with rapamycin. Furthermore, iso-
lated mitochondria from livers of nfκb1−/− mice produced increased
ROS when compared to age‐matched wt mice, which could be allevi-
ated by rapamycin treatment (Figure 4k).
F IGURE 2 Rapamycin ameliorates
several aging‐associated histological
parameters in nf‐κb1−/− mice. (a)
Representative images of H&E staining of
lung tissue sections from nf‐κb1−/− mice
fed a control or rapamycin‐supplemented
diet with quantifications of mean linear
intercept (MLI) at 9.5 months of age; (b)
representative images of H&E staining of
skin sections from 9.5‐month‐old nf‐κb1−/−
mice fed with control or rapamycin‐
supplemented diet plus quantifications of
mean epidermal thickness; (c)
representative images of heart sections
labelled with wheat germ agglutinin WGA
from 9.5‐month‐old nf‐κb1−/− mice fed
with control or rapamycin‐supplemented
diet plus quantifications of cross‐sectional
cardiomyocyte area. All data are
mean ± SEM (n = 4–8 mice per group).
*p < 005, **p < 0.01, ***p < 0.001 (One‐
way ANOVA)
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F IGURE 3 Rapamycin does not reduce inflammation in nf‐κb1−/− mice. (a) Serum cytokine array from wild‐type (n = 5) or nfκb1−/− mice
(n = 6) fed a control (−) or rapamycin‐supplemented (+) diet; (b) spleen weight, represented as percentage of total body weight in wild‐type or
nfκb1−/− mice fed control or rapamycin‐supplemented diet at 9.5 months of age; (c) IL‐6 mRNA levels in whole lung, or liver (f), tissue from
wild‐type or nfκb1−/− mice fed control or rapamycin‐supplemented diet, normalized to 18S; (d) ChIP analysis of RELA enrichment at the IL‐6
promoter in whole lung, or liver (g), from nfκb1−/− mice fed a control or rapamycin‐supplemented diet; (e) and (h) representative images of
CD68 immunohistochemical staining in lung or liver tissue sections, respectively, from wild‐type or nf‐κb1−/− mice fed with control or
rapamycin‐supplemented diet plus quantifications of CD68+ cells/field. Data represent group mean ± SEM (n = 3–7 mice per group). *p < 005,
**p < 0.01, ***p < 0.001 (One‐way ANOVA)
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F IGURE 4 Rapamycin reduces markers associated with cellular senescence and mitochondrial dysfunction in vivo and in vitro. (a)
Representative images of immunofluorescence in situ hybridization (immuno‐FISH) staining in lung airway epithelium, or hepatocytes in liver
sections (c) of nfκb1−/− mice fed control or rapamycin‐supplemented diet at 9.5 months of age. Images are maximum intensity projections of at
least 50 planes with areas of colocalization in single Z planes shown on the right. Graphs represent quantification of γH2A.X and telomere
signals in selected regions of interest (dotted lines); (b) frequencies of telomere‐associated foci (TAF) in small airway epithelial cells, or
hepatocytes (d), from 9.5‐month‐old wild‐type and nfκb1−/− mice fed a control or rapamycin‐supplemented diet; (e) p16 and p21 mRNA levels
in whole lung tissue from wild‐type or nfκb1−/− mice (9.5 months old) fed control or rapamycin‐supplemented diet, normalized to 18S; (f)
mouse adult fibroblasts (MAFs) isolated from the ears of wt or nfκb1−/− mice were induced to senescence by 10 Gy irradiation and cultured in
the presence or absence of rapamycin at 3% O2; (g) representative western blot showing phospho‐S6 (pS6), S6 and p21 expression in
senescent MAFs from wild‐type and nfκb1−/− mice treated with rapamycin (+) or DMSO (−) with quantifications on the right (h); (i)
representative images of senescence‐associated β‐galactosidase staining in MAFs from wild‐type or nfκb1−/− mice treated with rapamycin (+) or
DMSO (−) with quantifications of percentage positive cells shown on the right; (j) heatmap depicting fold change in indicated cytokines in
medium of proliferating and senescent MAFs from wild‐type and nfκb1−/− mice treated with or without rapamycin measured using a
Multiplexing LASER Bead Assay; (k) mitochondrial ROS (MitoSOX) levels in proliferating and senescent MAFs from wild‐type and nfκb1−/− mice
treated with or without rapamycin and hydrogen peroxide generation in isolated mitochondria from the livers of wild‐type and nfκb1−/− mice
(9.5 months old) fed a control or rapamycin‐supplemented diet. Data are mean ± SEM (n = 3–7 mice per group for all analyses). *p < 005,
**p < 0.01, ***p < 0.001 (One‐way ANOVA)
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3 | DISCUSSION
Previous studies have demonstrated that rapamycin treatment
extends lifespan and delays the onset of a number of age‐related
pathologies in wt mice (Harrison et al., 2009; Houssaini et al., 2018;
Lesniewski et al., 2017; Reifsnyder, Flurkey, Te, & Harrison, 2016),
possibly by reducing the tumour‐promoting abilities of senescent cells,
particularly the SASP (Herranz et al., 2015; Laberge et al., 2015). Here,
we aimed to understand the impact of rapamycin in the context of
enforced deregulation of the NF‐κB pathway, a major regulator of
aging and cancer. We report that rapamycin does not rescue the short-
ened lifespan and CLD in nfκb1−/− mice, which we speculate may be
due to its inefficiency in counteracting inflammaging.
Nevertheless, rapamycin reduced a range of shared aging and
senescence‐associated markers. These observations are supported by
the fact that the link between chronic inflammation and aging is, at
least in part, driven by the accumulation of senescent cells, as evi-
denced by the delayed onset of age‐related inflammatory patholo-
gies and improved healthspan upon elimination of senescent cells in
wild‐type mice and models of age‐related disease (Baker et al., 2016;
Ogrodnik et al., 2017; Schafer et al., 2017; Xu et al., 2018) and the
increased frequencies of senescent cells in the nfκb1−/− mouse (Jurk
et al., 2014). Indeed, there is increasing interest in finding therapies
to eliminate senescent cells or target specifically the deleterious
aspects of the senescent phenotype, including its pro‐inflammatory
and pro‐oxidant components (Birch & Passos, 2017).
We also report a reduction in mitochondrial ROS by rapamycin
treatment both in vitro and in mitochondria isolated from mouse liv-
ers, coupled to a reduction in TAF in nfκb1−/− mice. This together
with the fact that: (a) rapamycin can reduce mitochondrial ROS
(Miwa et al., 2014; Correia‐Melo et al., 2016); (b) mitochondrial ROS
can induce telomere dysfunction and accelerate senescence (Passos
et al., 2007); and (c) in addition to the paracrine effects of the SASP,
ROS leaked by senescent cells can also induce senescence in neigh-
bouring cells (Nelson et al., 2012), leading to the hypothesis that
improvements in mitochondrial function may contribute to reduced
activation of cellular senescence regulating pathways, which could
account for the improved overall healthspan in the nfκb1−/− mice.
Another potential mechanism by which rapamycin improves
healthspan is by preventing stem cell dysfunction. NF‐κb1−/− mice
have been shown to exhibit stem cell dysfunction and impaired
regeneration (Jurk et al., 2014). Interestingly, stem cell depletion in
mice has recently been shown to causally contribute to senescence
induction and premature aging phenotypes (Vilas et al., 2018). Fur-
thermore, mTOR has been shown to negatively impact on stem cell
function potentially via mitochondrial dysfunction and ROS genera-
tion (Chen et al., 2008; Sousa‐Victor et al., 2014). Thus, it is possible
that rapamycin prevents stem cell decline in NF‐kB1−/− despite
chronic inflammation.
It should be noted that our study was limited to male mice, and
with the same doses of rapamycin, effects on survival were stronger
in females than males (Harrison et al., 2009); thus, future investiga-
tions should account for gender effects.
In summary, our results show that rapamycin can ameliorate cer-
tain age‐related phenotypes irrespectively of the inflammatory bur-
den. Given the known tight relationship between inflammaging,
dysfunctional NF‐κB signalling and several age‐related diseases, our
results may have important clinical and conceptual implications.
4 | EXPERIMENTAL PROCEDURES
4.1 | Mice groups, treatments and housing
Experiments were performed on male nf‐κb1−/− mice on a pure
C57Bl/6 background and C57Bl/6 wild‐type controls. Mice were split
into two groups according to age and diet: (a) 9.5‐month‐old mice
fed a control or rapamycin‐supplemented diet (as described in Har-
rison et al., 2009) for 6 months prior to humane end point and (b)
lifespan mice (nf‐κb1−/− mice only) fed with a control or rapamycin‐
supplemented diet from 4 to 5 months old until moribund state fol-
lowed by humane end points. The different mice groups were
matched for age and randomly assigned for the treatments. Control
and rapamycin diets were purchase from TestDiet—control diet:
5LG6/122 PPM EUDRAGIT 3/8 #1814831 (5AS0) and encapsulated
rapamycin diet: 5LG6/122 PPM ENCAP RAP 3/8 #1814830 (5ARZ).
Mice were housed in cages (56 cm_38 cm_18 cm, North Kent Plas-
tics, Kent, UK) of groups of 4–6 that did not change from weaning.
Mice had ad libitum (AL) access to food and water and were moni-
tored weekly. Mice were housed at 20 ± 2°C under a 12 hr light/
12 hr dark photoperiod with lights on at 07:00 hr.
Maximum lifespan was estimated as the lifespan of the longest
living 1%–3% of the cohort. Medians were calculated from right‐cen-
sored Kaplan–Meier curves. Ethical approval was granted by the
LERC Newcastle University, UK. All experiments were undertaken in
compliance with UK Home Office legislation under the Animals (Sci-
entific Procedures) Act 1986. No statistical method was used to pre-
determine sample size. No animals or samples were excluded from
the analysis.
Organs and tissues were collected during necropsy and fixed
with either 10% formalin (VWR; 9713.9010) and paraffin embedding
for histochemical analysis or snap‐frozen in liquid nitrogen and
stored at −80°C for biochemical analysis.
4.2 | Frailty measurements
Frailty was assessed in nfκb1−/− mice using the Clinical Frailty Index
described by Whitehead et al. (2014). Body weight and temperature
are given as mean values and are not included in the sum frailty
index score. Mice were scored 0 for no frailty phenotype, 0.5 for
mild phenotype and 1 for severe phenotype. This was performed
simultaneously by two trained assessors, including an experienced
animal technician. Clinical examination was performed at the same
time of the day each time. Mice were observed in their home cage,
before being moved to a sterile hood. Body weight was recorded,
and surface temperature was measured using an infrared tempera-
ture probe (Raynger MX, Raytek).
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4.3 | Short‐ and long‐term memory tests
Short‐ and long‐term memory was assessed in nfκb1−/− mice using a
Barnes maze test. The maze consists of an open circular surface (diam-
eter = 92 cm), with a series of 20 holes (diameter = 5 cm) along the
border and four visual markers at 0°, 90°, 180° and 270° positions
(square, cross, triangle or circle). These visual markers are placed on
the walls around the maze, and the maze is elevated so that mice can-
not exit via the sides. Under one of these holes is attached the “target
box,” which the mouse can enter and provide refuge from the bright
and exposed open surface top. The experiment requires the subject to
learn the spatial position of this escape box relative to a number of
visual cues positioned on the surrounding walls. The mouse is placed
in an opaque pipe (diameter = 11 cm, height = 15 cm), in the centre
of the maze and allowed 10 s to calm. The pipe is removed, and the
timer started. An overhead camera, linked to a DVD recorder and
monitor, allows the performance of the mouse to be observed and
recorded. Each mouse is assigned one to one the four visual markers,
under which the escape box will be placed during training. In initial
run, naïve mice are guided to the escape hole and allowed to rest
inside for 2 min to acclimatize. The “Acquisition phase” follows this,
with mice running four trials per day, for 4 days. In each trial, the
mouse is given 3 min to find and enter the escape hole. If the mouse
does not find the hole in the allotted time then it is again guided to the
escape hole. The mouse is allowed to rest in the target box for 1 min.
Between trials, the board and escape box are wiped with 70% EtOH
to remove odour trails. Short‐term memory was tested 24 hr after
training on day 5 in a 90 s trial, without the target box present. Long‐
term retention is tested in the same fashion 12 days after training,
with no training between these trials. The number of times the mouse
moves its head over, or into, the target hole was recorded during these
trials was recorded.
4.4 | Forelimb grip strength analysis
Forelimb grip strength was assessed by allowing animals to grip a
suspended wire coat hanger with a diameter of 2 mm and a length
of 30 cm using its forelimbs. Time spent hanging from the wire fol-
lowing grip was recorded across 10 attempts up to a total of 90 s.
Completion was defined as having succeeded in hanging for a total
sum of 90 s. The test was terminated after 90 s or once 10 trials
were performed. Trials were defined as failures if the animal fell
from the wire, after which the timer was paused and the replaced
after a 20‐s resting period.
4.5 | Neuromuscular coordination analysis
Neuromuscular coordination was assessed using the tightrope test
(Jurk et al., 2014). Briefly, animals were placed on a horizontal bar,
with a diameter of 1.5 cm and a length of 60 cm, and time spent on
top of the bar was recorded. A trial was considered successful if the
animal could remain on the bar for 60 s without falling. Each mouse
was given five consecutive trials.
4.6 | Mouse adult fibroblast (MAFs) culture
MAFs were isolated from ear clippings from wild‐type and nfκb1−/−
mice and cultured as previously described (Ogrodnik et al., 2017).
Each primary cell line was derived from a separate donor. MAFs
were seeded and allowed to grow for 24 hr, and then, X‐ray irradi-
ated with 10 Gy using a PXI X‐Rad 225 (RPS Services Ltd) to induce
cellular senescence. MAFs were cultured at 3% O2.
4.7 | Tissue histology and morphometric analysis
Tissues were fixed in 10% formalin and embedded in paraffin. For
lung structural analysis, sections of the left lung were cut at 5 μm
and stained with H&E, as previously described (Birch et al., 2015).
Airspace size was determined on 10 randomly captured images for
each animal by the mean linear intercept method as described (Birch
et al., 2015) using ImageJ analysis software. Epidermal thickness was
determined on H&E sections (5 μm) of skin collected from the dorsal
region of the animal using ImageJ analysis software, as previously
described (Jurk et al., 2014).
Membrane staining for cardiac hypertrophy quantification was
performed with wheat germ agglutinin (WGA) labelling (Alexa Fluor®
647 conjugate, W32466, Invitrogen) as per manufacturer's instruc-
tions. Cardiomyocyte hypertrophy was assessed by cross‐sectional
area of cell membranes labelled with WGA, and troponin C was used
to identify cardiomyocytes. Only cardiomyocytes in the left ventricle
free wall were analysed and only in the areas in the subepicardium
region. To control for tissue orientation, only cardiomyocytes that
were surrounded by capillaries all displaying a cross‐sectional orien-
tation were analysed.
4.8 | Crosslinked chromatin immunoprecipitation
(ChIP) assay
ChIP assay was carried out using 25 μg crosslinked chromatin pre-
pared from nfκb1−/− livers and lung. Briefly, the chromatin was pre-
pared by resuspending powdered, frozen lung and liver in 10 ml cold
PBS with protease inhibitors and crosslinked with 1% formaldehyde
for 5 min. The reaction was stopped by adding 0.125 M glycine, cells
spun and pellet resuspended in lysis buffer (1% SDS, 10 mM EDTA,
50 mM Tris–HCl (pH 8.1)) for 20 min before sonication for 10 min
(10 cycles of 30 s on, 30 s off) in Diagenode Bioruptor. The soni-
cated material was spun down, and chromatin‐containing super-
natant was collected. 25 μg of chromatin was then incubated with
5 μg of anti‐p65 antibody (sc109x, Santa Cruz) or control antibody
(ab46540, Abcam) overnight at 4°C. The complexes were collected
using 50 μl of blocked Staph A membranes, which were then serially
washed, complexes eluted off and crosslinks reversed. Genomic
DNA was purified and used in quantitative PCR with mIL‐6 primers.
Each PCR was performed in triplicate, and the analysis was repeated
at least three times from independent ChIP experiments. A signal
intensity value for each sample was calculated from the average of
the experiments. Average values of eluates were normalized to
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average values of control antibody sample and expressed as fold
enrichment above background. PCR amplification was carried out
using the primers forward primer 5′‐AAGCACACTTTCCCCTTCCT‐3′
and reverse primer 5′‐TCATGGGAAAATCCCACAT‐3′.
4.9 | Sen‐β‐Gal assay
Analysis of Sen‐β‐Gal activity in MAFs was carried out as previously
described (Jurk et al., 2014).
4.10 | Immunocytochemistry
Analysis of Ki67 positivity in MAFs was performed as previously
described (Jurk et al., 2014). Briefly, MAFs were washed with PBS
and fixed for 10 min with 2% paraformaldehyde. Cells were perme-
abilized for 45 min, and the primary antibody (anti‐Ki67 no.
ab15580, rabbit polyclonal, Abcam, 1:50) was applied overnight at
4°C, followed by incubation with Alexa Fluor secondary antibody
(1:2,000; Molecular Probes) for 30 min at room temperature. Cells
were stained with DAPI and mounted in VECTASHIELD Mounting
Media.
4.11 | Western blotting
Western blotting was carried out on protein isolated from MAFs as
previously described (Jurk et al., 2014). Primary antibodies against
phospho‐S6 (Ser235/236) (Rabbit monoclonal no. 4858, Cell Sig-
nalling, 1:1,000), S6 (Rabbit monoclonal no. 2217, Cell Signalling,
1:1,000), p21 (Rabbit monoclonal no. 2947, Cell Signalling, 1:1,000)
and β‐tubulin (Rabbit polyclonal no. 2146, Cell Signalling, 1:2,000)
were applied overnight at 4°C. Goat anti‐rabbit IgG‐HRP conjugated
secondary antibody (A0545, Sigma‐Aldrich) was applied for 1 hr at
room temperature (1:5,000).
4.12 | Immunohistochemistry (IHC)
IHC was performed and analysed as previously described (Birch
et al., 2015). Antibodies against CD68 (Polyclonal Antibody (1:100,
aviva system biology OABB00472)) and α‐SMA were applied over-
night at 4°C. Staining was analysed with a NIKON ECLIPSE‐E800
microscope, and images were captured with a Leica DFC420 camera
using the LAS software (Leica). Staining was quantified in a blinded
fashion on 10 random images captured per tissue section.
4.13 | Immuno‐FISH
For analysis of telomere‐associated foci, immunofluorescence cou-
pled with telomere‐fluorescence in situ hybridization (immuno‐FISH)
was performed. Tissues were stained and analysed as described in
Hewitt et al. (2012). Briefly, anti‐γH2A.X (S139) (no. 9718, Rabbit
monoclonal, Cell Signalling, 1:200) immunofluorescence was carried
out followed by crosslinking tissues with 4% formaldehyde for
20 min. Tissues were denatured for 10 min at 80°C in hybridization
buffer (70% formamide), 25 mM MgCl2, 0.1 M Tris (pH 7.2), 5%
blocking reagent (Roche)) containing 2.5 μg ml Cy‐3‐labelled telom-
ere‐specific (CCCTAA) peptide nucleic acid probe (Panagene), fol-
lowed by hybridization for 2 hr at room temperature in the dark. In‐
depth Z‐stacking was used (a minimum of 40 optical slices with
×100 objective) followed by Huygens (SVI) deconvolution.
4.14 | Quantitative RT‐PCR
Q‐PCR analysis was performed as previously described in Correia‐
Melo et al. (2016). mRNA expression levels were normalized to the
expression of the 18S gene. Q‐PCR was run in triplicate using the
following primers:
p21 Fw: 5′‐CCTGGTGATGTCCGACCTG‐3′
p21 Rv: 5′‐CCATGAGCGCATCGCAATC‐3′
p16 Fw: 5′‐TTGCCCATCATCATCACCT‐3′
p16 Rv: 5′‐GGGTTTTCTTGGTGAAGTTCG‐3′
18S Fw: 5′‐CGGCTACCACATCCAAGGAA‐3′
18S Rv: 5′‐AGCCGCGGTAATTCCAGC‐3′
IL‐6 Fw: 5′‐TGATTGTATGAACAACGATGATGC‐3′
IL‐6 Rv: 5′‐GGACTCTGGCTTTGTCTTTCTTGT‐3′
4.15 | Cytokine array
Blood serum was collected from wild‐type and nfκb1−/− mice at
9.5 months of age. Senescence was induced in wild‐type and nfκb1−/
− MAFs by X‐ray irradiation (10 Gy). At day 9 (with or without irradi-
ation), cells were cultured in serum‐free media for 24 hr and media
were collected for analysis.
Both media and blood serum were analysed for expression of
several mouse cytokine and chemokines (MD31) using a Multiplexing
LASER Bead Assay (Eve Technologies).
4.16 | Sirius red staining
Sirius red staining was carried out on 10% formalin‐fixed, paraffin‐
embedded liver sections (5 μm) to assess collagen deposition. Briefly,
sections were dewaxed in Histoclear and rehydrated through serial
ethanol dilutions. Sections were treated with 0.2% phospho molyb-
dic acid for 5 min followed by incubation with Picro‐Sirius Red for
2 hr at room temperature. Slides were washed with 0.01% HCl and
dehydrated through graded ethanol solutions. Slides were mounted
with DPX and imaged using a Leica DFC420 camera using the LAS
software (Leica) connected to a NIKON ECLIPSE‐E800 microscope.
Staining was quantified in a blinded fashion on 10 random images
captured per section.
4.17 | Mitochondrial ROS measurements
Mitochondrial superoxide levels were measured in MAFs by flow
cytometry by incubation with 5 μM MitoSOX probe (Molecular
Probes, Invitrogen) as previously described (Passos et al., 2007).
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Mitochondrial hydrogen peroxide release in isolated mitochondria
from liver was measured fluorometrically in the presence of exoge-
nous superoxide dismutase (15 U/ml), horseradish peroxidise (2 U/ml)
and Amplex Red (50 mM) at 37°C, and the fluorescence signals were
calibrated against a hydrogen peroxide standard as previously
described in Miwa et al. (2014).
4.18 | Statistical analyses
One‐way ANOVA, two‐tailed t test, Wilcoxon–Mann–Whitney and
Kruskal–Wallis test were assessed using GraphPad Prism Version
6.0. Linear and non‐linear regression analysis test and Kaplan–Meier
survival curves were conducted using Sigma Plot versus 11.0.
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